Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) SOUTH SAN FRANCISCO, Calif., May 13, 2025 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financia ...